Naturally Adam F., who was ignoring AVXL for a whi
Post# of 1460
Quote:
Anavex Life Sciences said Thursday that its experimental treatment for Alzheimer’s disease slowed the rate of cognitive decline in a clinical trial — but only by changing the study’s primary efficacy goals, omitting patients from the analysis, randomly altering data, making basic math errors, whistling past safety concerns, and using nonsensical statistical tests.
Put all those issues aside, and Anavex’s drug performed wonderfully. In fantasy land.
To read the whole article, you have to have a paid subscription, which I would never do. Why give them more money to finance their short operations against our stocks? But just in case you have a subscription, or you want to give them ad income by clicking on this link that has NO more information that the quote I posted, here it is:
https://www.statnews.com/2022/12/02/an-anavex...-152820318